Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 56 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: NAD Clear all
Completed Phase 2 Interventional

Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome

NCT04604704
View directory record Official record
Conditions
Covid19, Long COVID-19, Post-COVID-19 Syndrome
Interventions
Naltrexone, NAD+
Drug · Dietary Supplement
Lead sponsor
AgelessRx
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Oct 19, 2026, 4:26 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Combination Gerotherapeutic Interventions for Healthspan Improvement

NCT07475546
View directory record Official record
Conditions
Healthspan Improvement, Aging, Longevity
Interventions
Rapamycin, Naltrexone, Metformin, NAD+, GSH, Infinite Supplement, Placebo/control, B12, Intervention: Guided Meditation Program, Control: Podcast Listening Activity, Control: Standard Exercise Regimen, Intervention: Structured Exercise Program
Drug · Dietary Supplement · Behavioral
Lead sponsor
AgelessRx
Industry
Eligibility
60 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 19, 2026, 4:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition

NCT02942888
View directory record Official record
Conditions
Mild Cognitive Impairment, NAD
Interventions
Nicotinamide riboside, Sugar Pill
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
65 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 2, 2021 · Synced Oct 19, 2026, 4:26 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1a Single Ascending Dose Study of MIB-725 in Healthy Adults

NCT06815991
View directory record Official record
Conditions
Healthy Adults
Interventions
MIB-725
Drug
Lead sponsor
Metro International Biotech, LLC
Industry
Eligibility
19 Years to 60 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 19, 2026, 4:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nicotinamide Adenine Dinucleotide Responses to a Nutritional Supplement

NCT07428889
View directory record Official record
Conditions
Healthy Adult
Interventions
Proprietary Nutritional Supplement, Placebo Supplement
Dietary Supplement
Lead sponsor
Shaklee Corporation
Industry
Eligibility
45 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 19, 2026, 4:26 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Validation of NAD+ Measurements for Human Clinical Studies

NCT07416786
View directory record Official record
Conditions
Healthy Adults
Interventions
Oral NR Supplementation
Dietary Supplement
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 110 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 19, 2026, 4:26 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Absorption and Tolerability of Injectable Administration of Niagen®+, as Compared to NAD+

NCT06919328
View directory record Official record
Conditions
Healthy Aging
Interventions
Niagen®, NAD+, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraceuticals Research Institute
Other
Eligibility
40 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Huntsville, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 19, 2026, 4:26 PM EDT
Recruiting Phase 2 Interventional

NAD Augmentation in Diabetes Kidney Disease

NCT05759468
View directory record Official record
Conditions
Type2diabetes, Diabetic Kidney Disease
Interventions
Investigational Product - MIB 626, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 19, 2026, 4:26 PM EDT
Terminated Phase 4 Interventional Results available

Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease

NCT01147042
View directory record Official record
Conditions
IFN-Gamma Therapy, CGD Gene Mutation, CGD Response to IFNg, CGD - Chronic Granulomatous Disease, Immunodeficiency Disease
Interventions
IFN-gamma
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 19, 2026, 4:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes

NCT02721537
View directory record Official record
Conditions
Concussion, Mild
Interventions
Nicotinamide Riboside, Matching placebo
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
2
States / cities
Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 19, 2026, 4:26 PM EDT
Not yet recruiting Phase 2 Interventional

Nicotinamide for Retinal Protection in Primary Open-Angle Glaucoma (NADIR Trial)

NCT07808333
View directory record Official record
Conditions
Glaucoma, Open-angle, Primary Open Angle Glaucoma (POAG)
Interventions
Nicotinamide, Standard Glaucoma Therapy
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
40 Years to 80 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 4:26 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Renewal-NAD+: A Study of Oral NAD+ and Its Multi-omic Impact in a Healthy Cohort

NCT07336836
View directory record Official record
Conditions
Health Adult Subjects, Healthy Participants
Interventions
LathMized TM NAD+ (LNAD+), Control (placebo)
Dietary Supplement · Other
Lead sponsor
BioNADrx Holdings, Inc. Bryleos
Industry
Eligibility
45 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Oct 19, 2026, 4:26 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

The Effect of NAD Supplementation on Brain Vascular Health in Aging

NCT05483465
View directory record Official record
Conditions
Aging
Interventions
Nicotinamide riboside, Placebo
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
60 Years to 85 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 19, 2026, 4:26 PM EDT
Completed Phase 1Phase 2 Interventional

Sirtuin-NAD Activator in Alzheimer's Disease

NCT05040321
View directory record Official record
Conditions
Alzheimer's Disease (Incl Subtypes), Dementia
Interventions
MIB-626, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
55 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 19, 2026, 4:26 PM EDT
Completed No phase listed Observational

Genetic Variants in Nicotinamide Adenine Dinucleotide (NAD) Synthesis Pathway

NCT03799705
View directory record Official record
Conditions
Vacterl Association, Congenital Malformation
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
0 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Oct 19, 2026, 4:26 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Tracing the Metabolic Flux of Orally Administered NAD+ Precursors

NCT06882096
View directory record Official record
Conditions
Healthy Adults
Interventions
Nicotinamide Mononucleotide (NMN), Nicotinamide (NAM)
Drug
Lead sponsor
Metro International Biotech, LLC
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 19, 2026, 4:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

NAD Therapy for Improving Memory and Brain Blood Flow in Older Adults With Mild Cognitive Impairment

NCT03482167
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Niagen®, Placebo
Drug · Other
Lead sponsor
University of Delaware
Other
Eligibility
60 Years to 90 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 19, 2026, 4:26 PM EDT
Recruiting Not applicable Interventional

Mechanistic Study of Nicotinamide Riboside on NAD+ Biology in Individuals With Combined Pulmonary Hypertension

NCT07563322
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Nicotinamide Riboside (NR), Placebo
Dietary Supplement · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 19, 2026, 4:26 PM EDT
Completed Phase 2 Interventional

Role of QRX-3 in Chronic Kidney Disease Patients in Outpatients Clinics

NCT06948292
View directory record Official record
Conditions
Chronic Kidney Disease Stages 3-5, Diabetic Kidney Disease, Hypertensive Kidney Disease
Interventions
QRX-3
Drug
Lead sponsor
Ebima Clifford Okundaye
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Pasedena, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Oct 19, 2026, 4:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels

NCT06505967
View directory record Official record
Conditions
NAD+ Levels in the Blood
Interventions
Qualia NAD+, Placebo
Dietary Supplement · Other
Lead sponsor
Qualia Life Sciences
Industry
Eligibility
40 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 19, 2026, 4:26 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Brain NAD in Alzheimer's Disease

NCT07127510
View directory record Official record
Conditions
Alzheimer Disease (AD)
Interventions
Not listed
Lead sponsor
Florida Atlantic University
Other
Eligibility
65 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 19, 2026, 4:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Open-label Study to Assess Increasing Levels of NAD+(Nicotinamide Adenine Dinucleotide)

NCT03707652
View directory record Official record
Conditions
Increase in Blood Levels of Nicotinamide Adenine Dinucleotide (NAD+)
Interventions
Oral supplement A, Oral supplement B, Oral supplement C, Oral supplement D, Oral Supplement D in combination with oral supplement C
Dietary Supplement
Lead sponsor
Supplement Formulators, Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 19, 2026, 4:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in Aging

NCT03818802
View directory record Official record
Conditions
Healthy Elderly Volunteers
Interventions
Nicotinamide Riboside, Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years to 80 Years · Female only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 19, 2026, 4:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effectiveness of Qualia NAD+ Supplementation on NAD Levels

NCT06812416
View directory record Official record
Conditions
Intracellular NAD+ Levels
Interventions
Qualia NAD+, Rice Flour Placebo
Dietary Supplement
Lead sponsor
Qualia Life Sciences
Industry
Eligibility
40 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 19, 2026, 4:26 PM EDT